MENLO PARK, CA, October 23, 2023. LamdaGen Corporation, a developer of nano-based plasmonic biosensor technology has entered into a subcontract with MRIGlobal in collaboration with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to undertake proof-of-concept studies for the detection of a priority biothreat using immobilized phage receptor-binding proteins, bacterial cell receptor proteins and vegetative bacterial cells. The agreement also includes an analytical sensitivity (LOD) comparison study of the respective pathogen’s spores employing immobilized antibodies. This collaboration aims to leverage plasmonic biosensor technology to enhance and fortify biological threat detection capabilities.
The initiative is supported by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.